https://www.facingourrisk.org/research-clinical-trials/study/330/screening-study-for-pancreatic-cancer
Prevention
Pancreatic cancer screening study for people with BRCA, ATM, or PALB2 genetic mutations
This study will look at how often routine MRI scans detect abnormal findings in people with genetic mutations linked to hereditary cancer, specifically BRCA1, BRCA2, ATM, and PALB2, who are undergoing pancreatic cancer screening. Researchers aim to determine how frequent there are abnormal MRI and endoscopic ultrasound (EUS) results, as well as the occurrence of high-grade pancreatic precancerous lesions and pancreatic cancer. The study will also review the rate of procedures like biopsies and surgeries among participants.
https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Prevention
Screening study for people with a mutation linked to prostate cancer risk
The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer
Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy
Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:
https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).
https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer
Prevention
Screening using MRI for men at risk of developing prostate cancer
This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Prevention
People at high risk for prostate cancer due to an inherited mutation
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk
The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. The study is enrolling people with an inherited mutation with a gene linked to ovarian cancer, such as BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Prevention
Screening study to detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + PALB2
6 results
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://clinicaltrials.gov/study/NCT05608694)
Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://clinicaltrials.gov/study/NCT03568630)
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with Inherited Genetic Risk
NCT ID: NCT02478892 (https://clinicaltrials.gov/study/NCT02478892)
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT ID: NCT06151223 (https://clinicaltrials.gov/study/NCT06151223)
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT ID: NCT03250078 (https://clinicaltrials.gov/study/NCT03250078)
Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer
NCT ID: NCT06888388 (https://clinicaltrials.gov/study/NCT06888388)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.